Serum levels of 25-hydroxyvitamin D and occurrence of musculoskeletal diseases, such as osteoporosis, knee osteoarthritis and lumbar spondylosis: A three-year follow-up of the road study.
Serum levels of 25-hydroxyvitamin D and occurrence of musculoskeletal diseases, such as osteoporosis, knee osteoarthritis and lumbar spondylosis: A three-year follow-up of the road study.
复制标题
25-羟基维生素 D 的血清水平与肌肉骨骼疾病（如骨质疏松症、膝骨关节炎和腰椎病）的发生：道路研究的三年随访。
DOI：
10.1007/s00198-014-2844-9
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Akune T
中科院分区：
文献类型：
--
作者：
Yoshimura N;Muraki S;Oka H;Nakamura K;Kawaguchi H;Tanaka S;Akune T
摘要采用基于人群的队列研究设计评估血清 25-羟基维生素 D 水平与肌肉骨骼疾病发生的关系，结果显示血清 25-羟基维生素 D 水平可以预测 3 年内股骨颈骨质疏松症的发生，但不能预测膝骨关节炎或腰椎的发生 简介本研究的目的是阐明普通人群中血清 25-羟基维生素 D (25D) 水平与骨质疏松症和骨关节炎发生之间的关系。方法骨关节炎/骨质疏松症针对残疾的研究是一项大规模的基于人群的队列研究，于 2005 年至 2007 年进行。测量了 1,683 名参与者的血清 25D 水平。其中，1,384 人 (81.9%) 于 3 年后完成了第二次跟踪调查。骨质疏松症是根据世界卫生组织的标准定义的，其中骨质疏松症是通过骨矿物质密度 (BMD) 的 T 分数诊断的，该分数比正常 BMD 低 2.5 个标准差 (SD)。使用配对X射线片将膝骨关节炎和腰椎病定义为Kellgren-Lawrence等级≥2。累积发病率是根据基线和第二次调查之间使用世界卫生组织骨质疏松症标准或骨关节炎 Kellgren-Lawrence 分级的测量变化来确定的。结果两次调查中 1,384 名参与者的平均 (SD) 血清 25D 水平为 23.4 ng/mL (6.5)。 L2-4 和股骨颈骨质疏松症的年累积发病率分别为 0.76% 和 1.83%/年。膝骨关节炎和腰椎病的发病率分别为 3.3%/年和 11.4%/年。调整潜在的相关因素后，逻辑回归分析显示，随着血清 25D 水平的增加，发生股骨颈骨质疏松症的比值比显着降低（+1 SD；比值比 0.67；95% 置信区间 0.49–0.92；p= 0.014）。 结论 较高的血清 25D 水平可能预防股骨颈骨质疏松症的发生 颈椎病，但不包括膝骨关节炎、腰椎病或 L2-4 骨质疏松症。
SummaryAssessment of serum 25-hydroxyvitamin D levels in association with the occurrence of musculoskeletal diseases using a population-based cohort study design revealed that serum 25-hydroxyvitamin D levels could predict the occurrence of osteoporosis at the femoral neck within 3 years, but not the occurrence of knee osteoarthritis or lumbar spondylosis.IntroductionThe aim of this study is to clarify the association between serum 25-hydroxyvitamin D (25D) levels and occurrence of osteoporosis and osteoarthritis in the general population.MethodsThe Research on Osteoarthritis/Osteoporosis Against Disability study, a large-scale population-based cohort study, was performed during 2005–2007. Serum 25D levels were measured in 1,683 participants. Of these, 1,384 individuals (81.9 %) completed a second follow-up survey 3 years later. Osteoporosis was defined according to World Health Organization criteria, in which osteoporosis is diagnosed by T-scores of bone mineral density (BMD) that are 2.5 standard deviations (SD) less than normal BMD. Knee osteoarthritis and lumbar spondylosis were defined as Kellgren–Lawrence grade ≥2, using paired X-ray films. Cumulative incidences were determined according to changes in measurements using World Health Organization criteria for osteoporosis or Kellgren–Lawrence grades for osteoarthritis between the baseline and second survey.ResultsThe mean (SD) serum 25D level of the 1,384 participants in both surveys was 23.4 ng/mL (6.5). The annual cumulative incidences of osteoporosis at L2–4 and the femoral neck were 0.76 and 1.83 %/year, respectively. The incidences of knee osteoarthritis and lumbar spondylosis were 3.3 and 11.4 %/year, respectively. After adjusting for potential associated factors, logistic regression analyses revealed that the odds ratio for the occurrence of femoral neck osteoporosis significantly decreased as serum 25D levels increased (+1 SD; odds ratio 0.67; 95 % confidence interval 0.49–0.92;p= 0.014).ConclusionsHigher serum 25D levels may prevent the occurrence of osteoporosis at the femoral neck, but not knee osteoarthritis, lumbar spondylosis, or osteoporosis at L2–4.